Login to Your Account



BETTER KEPPRA TO SEIZE MARKET?

Add-on nauseam: Change epilepsy drugs vocabulary, pleads Briviact researcher

By Randy Osborne
Staff Writer

Monday, February 22, 2016

The principal investigator for the original proof-of-concept study with just-approved epilepsy drug Briviact (brivaracetam) told BioWorld Today she's campaigning to get the FDA to cut the "add-on" description for such therapies, because there is "no indication that a drug that works as an add-on would not work by itself," and the tag is confusing to everyone – including payers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription